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ABSTRACT
A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown 
orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic 
(PDOX) model. Seven weeks after implantation, PDOX nude mice were divided into the 
following groups: untreated control (n = 7); gemcitabine (100 mg/kg, i.p., once a week 
for 2 weeks, n = 7); cobimetinib (5 mg/kg, p.o., 14 consecutive days, n = 7); trametinib 
(0.3 mg/kg, p.o., 14 consecutive days, n = 7); trabectedin (0.15 mg/kg, i.v., once a 
week for 2 weeks, n = 7); temozolomide (25 mg/kg, p.o., 14 consecutive days, n = 7); 
carfilzomib (2 mg/kg, i.v., twice a week for 2 weeks, n = 7); bortezomib (1 mg/kg, 
i.v., twice a week for 2 weeks, n = 7); MK-1775 (20 mg/kg, p.o., 14 consecutive days, 
n = 7); BEZ-235 (45 mg/kg, p.o., 14 consecutive days, n = 7); vorinostat (50 mg/kg, 
i.p., 14 consecutive days, n = 7). Only the MEK inhibitors, cobimetinib and trametinib, 
regressed tumor growth, and they were more significantly effective than other therapies 
(p < 0.0001, respectively), thereby demonstrating the precision of the PDOX models of 
PDAC and its potential for individualizing pancreatic-cancer therapy.
INTRODUCTION
Gemcitabine (GEM) is first-line therapy for pancreatic 
cancer [1, 2] with a poor response rate of approximately 
10% [3]. Novel drugs tested on pancreatic cancer include 
MEK inhibitors (cobimetinib [COB], trametinib [TRA]) 
[5–8], an PI3K/mTOR inhibitor (BEZ-235) [4–9], an 
HDAC inhibitor (vorinostat) [10], proteasome inhibitors 
(bortezomib, carfilzomib) [11, 12], a Wee-1 inhibitor 
(MK-1775) [13], temozolomide (TEM) [14] and trabectedin 
(TRAB) [15–17]. Whether a patient’s tumor is sensitive 
to any of these drugs is not knowable a priory. Genetic 
profiling can provide important information, but does not 
necessarily match drug sensitivity [18].
Clinically-relevant mouse models of pancreatic 
cancer could enable precision therapy based on the 
individual patient tumor. For this purpose, our laboratory 
pioneered the patient-derived orthotopic xenograft 
(PDOX) nude-mouse model with the technique of surgical 
orthotopic implantation (SOI), including breast cancer 
[19], ovarian cancer [20], lung cancer [21], cervical 
cancer [22], colon cancer [23–25], stomach cancer [26], 
melanoma [18, 27–29], sarcoma [30–34], as well as 
pancreatic cancer [35–38]. The PDOX model, developed 
by our laboratory over the past 28 years, has many 
advantages, including a patient-like metastatic pattern, 
over subcutaneous-transplant models which are growing 
ectopically under the skin and very rarely metastasize [39].
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In a previous PDOX study of a BRAF-V600E-
mutant melanoma, TRA, an MEK inhibitor, was the only 
agent of the 4 tested that caused tumor regression. Another 
MEK inhibitor, COB, could slow but not arrest growth 
or cause regression of the melanoma. The patient in this 
study had a BRAF-V600E-mutant melanoma and would 
be considered to be a strong candidate for vemurafenib 
(VEM) as first-line therapy, since VEM targets this 
mutation. However, VEM was not effectivein the PDOX 
model. The PDOX model thus helped identify the very-
high efficacy of TRA against the melanoma PDOX 
and is a promising drug for this patient. These results 
demonstrated the powerful precision of the PDOX model 
for cancer therapy, not achievable by genomic analysis 
alone [18]. 
Therefore, in the present study, in a PDOX nude-
mouse model with pancreatic cancer from a patient we 
evaluated TRA and COB and 8 other drugs to find the 
best treatment strategy for this patient and demonstrate the 
precision of the pancreatic-cancer PDOX model. As with 
the melanoma PDOX, TRA and COB were most effective 
in the pancreatic cancer PDOX. 
RESULTS AND DISCUSSION
All tested drugs, including GEM, COB, TRA, TRAB, 
TEM, carfilzomib, bortezomib, BEZ-235, vorinostat, 
inhibited tumor growth in the pancreatic cancer PDOX 
compared to untreated control (p < 0.0001, respectively) 
on day 14 after treatment initiation. However, only the 
MEK inhibitors, COB and TRA, regressed tumor growth 
and they were significantly more effective than other drugs 
(p < 0.0001, respectively) including GEM that is widely 
used as first line standard therapy for pancreatic cancer 
(p < 0.0001). There was no significant difference between 
COB and TRA (p = 0.0988) (Figures 1, 2). 
The relative body weight on day 14 compared with 
day 0 did not significantly differ between any treatment 
group or untreated control (Figure 3). There were no 
animal deaths in any groups.
Histologically, the untreated control tumor was 
mainly comprised of viable cells, in contrast, necrosis was 
observed in the tumor treated with COB (Figure 4). 
GEM is first-line therapy for pancreatic cancer, but 
the response rate is only approximately 10% [3]. In the 
present study, GEM could not arrest or regress the tumor 
growth but showed inhibition compared to the untreated 
control. In contrast, COB and TRA regressed the tumor 
and were significantly more effective than GEM. These 
results suggest that MEK inhibitors might be used as first 
line therapy for this patient.
Although, the present patient’s tumor was sensitive 
to MEK inhibitors in the PDOX models. Other patients’ 
tumors may be sensitive for other drugs such as TRAB, 
TEM, carfilzomib, bortezomib, MK-1775, BEZ-235, 
or vorinostat, as well as GEM. A PDOX model enables 
precise, individualized therapy, especially for recalcitrant 
disease such as pancreatic cancer [18].
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [40–45]. 
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
Animals were housed in a barrier facility on a high efficacy 
particulate arrestance (HEPA)-filtered rack under standard 
conditions of 12-hour light/dark cycles. The animals were 
fed an autoclaved laboratory rodent diet. All mouse surgical 
procedures and imaging were performed with the animals 
anesthetized by subcutaneous injection of a ketamine 
mixture (0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/
kg xylazine, and 0.48 mg/kg acepromazine maleate). The 
response of animals during surgery was monitored to ensure 
adequate depth of anesthesia. The animals were observed 
on a daily basis and humanely sacrificed by CO
2
 inhalation 
if they met the following humane endpoint criteria: severe 
tumor burden (more than 20 mm in diameter), prostration, 
significant body weight loss, difficulty breathing, rotational 
motion, and body temperature drop. All animal studies were 
conducted in accordance with the principles and procedures 
outlined in the National Institutes of Health Guide for the 
Care and Use of Animals under Assurance Number A3873-1 
[18, 27–29].
Patient-derived tumor
The pancreatic cancer was resected in the 
Department of Surgery, University of California, San 
Diego (UCSD). Written informed consent was provided 
by the patient, and the Institutional Review Board (IRB) 
of UCSD approved this experiment.
Establishment of PDOX models of pancreatic 
cancer by surgical orthotopic implantation (SOI)
A fresh sample of pancreatic cancer of the patient 
was obtained and transported immediately to the 
laboratory at AntiCancer, Inc., on wet ice. The sample was 
cut into 5-mm fragments and implanted subcutaneously in 
nude mice. After five weeks, the subcutaneously-implanted 
tumors grew to more than 10 mm in diameter. The 
subcutaneously-grown tumors were then harvested and 
cut into small fragments (3 mm3). After nude mice were 
anesthetized with the ketamine solution described above, 
a 1–2 cm skin incision was made on the left side abdomen 
through the skin, fascia and peritoneum and pancreas was 
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exposed. Surgical sutures (8–0 nylon) were used to implant 
tumor fragments onto the tail of pancreas to establish the 
PDOX model [35–38]. The wound was closed with a 
6–0 nylon suture (Ethilon, Ethicon, Inc., NJ, USA.
Treatment study design
PDOX mouse models were randomized into the 
following groups of 7 mice each: untreated control (n = 7); 
GEM (100 mg/kg, i.p., once a week for 2 weeks, n = 7); COB 
(5 mg/kg, p.o., 14 consecutive days, n = 7); TRA 
(0.3 mg/kg, p.o., 14 consecutive days, n = 7); TRAB 
(0.15 mg/kg, i.v., once a week for 2 weeks, n = 7); TEM 
(25 mg/kg, p.o., 14 consecutive days, n = 7); carfilzomib 
(2 mg/kg, i.v., twice a week for 2 weeks, n = 7); bortezomib 
(1 mg/kg, i.v., twice a week for 2 weeks, n = 7); MK-1775 
(20 mg/kg, p.o., 14 consecutive days, n = 7); BEZ-235 
(45 mg/kg, p.o., 14 consecutive days, n = 7); vorinostat 
Figure 1: Macroscopic evaluation of therapeutic efficacy. (A) Control. (B) Tumor treated with gemcitabine (GEM). (C) Treatment 
with cobimetinib (COB). White arrows show PDOX tumors on the pancreas. Scale bars: 5 mm.
Figure 2: Quantitative treatment efficacy of 10 drugs. Line graph shows relative tumor volume at post-treatment relative to 
pre-treatment tumor volume. All treatments significantly inhibited tumor growth compared to untreated control (p < 0.0001). Only MEK 
inhibitors (COB, TRA) regressed tumor growth. Error bars: ± SD.
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(50 mg/kg, i.p., 14 consecutive days, n = 7). Tumor length 
and width were measured both pre- and post-treatment. 
Tumor volume was calculated with the following formula: 
Tumor volume (mm3) = length (mm) × width (mm) × width 
(mm) × 1/2. Data are presented as mean ± SD. The tumor 
volume ratio is defined at the tumor volume at a post-
treatment point relative to pre-treatment tumor volume.
Imaging of the pancreatic cancer PDOX model
Imaging of the macroscopic tumor was performed with the 
OV100 Small Animal Imaging System (Olympus, Tokyo, Japan). 
Histological examination
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (5 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocols. Histological examination was performed 
with a BHS System Microscope (Olympus Corporation, 
Tokyo, Japan). Images were acquired with INFINITY 
ANALYZE software (Lumenera Corporation, Ottawa, 
Canada) [18, 29].
Figure 3: Effect of each drug on mouse body weight. Bar graph shows relative body weight in each treatment group at post-
treatment relative to pre-treatment. Error bars: ± SD.
Figure 4: Tumor histology after treatment. (A) Untreated control. (B) Treated with COB. Scale bars: 100 μm
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Statistical analysis
JMP version 11.0 was used for all statistical 
analyses. Significant differences for continuous variables 
were determined using the Mann-Whitney U test. Line 
graphs express mean values and error bars show standard 
deviation (SD). A probability value of P ≤ 0.05 was 
considered statistically significant.
CONCLUSIONS
In the present study, the PDOX model identified the 
ability of MEK inhibitors to regress a pancreatic cancer 
PDOX. That COB and TRA caused tumor regression 
indicated their potential efficacy for the patient donor of 
the PDOX in the present study. These results demonstrate 
the powerful precision of the PDOX model to distinguish 
the most effective of the 10 drugs tested.
Future experiments will test the present and other 
pancreatic cancer PDOX models with various therapies 
and compare the results with clinical outcome. 
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